Taking Elmiron for the long term may seem like a good idea, but there are a number of potential complications that can occur. These include glaucoma, cataracts, macular degeneration and pigmentary maculopathy.
Earlier this year, Emory University researchers discovered that the long-term use of Elmiron, a prescription drug used to treat interstitial cystitis (IC), was associated with a unique type of macular eye damage. These findings were published in the November issue of Ophthalmology.
The macula is a small area in the back of the eye that helps you see things that are directly in front of you. As you age, the macula deteriorates and can cause vision problems. Some people have rapid vision loss, while others have slow progression of the disease. The condition is often referred to as macular degeneration.
The macula is a part of the retina that is vital for central vision. In order to protect the macula, the Elmiron label recommends not using the drug for more than a year, and to see a doctor when you experience changes in your vision.
The label also warns that the drug may lead to an increase in the incidence of macular damage. A number of studies have shown that the macula is vulnerable to damage when the person uses Elmiron for a long period of time.
Several studies have found that long-term use of Elmiron can cause retinal damage. These findings have led to scores of lawsuits filed against the manufacturer of the drug. These lawsuits seek damages for pain and suffering, medical expenses, lost income, and permanent vision loss.
According to an Emory University study, patients who took the drug for interstitial cystitis (IC) had a higher risk of developing a new type of macular eye damage. In the study, six patients who had been taking Elmiron for years developed this type of maculopathy. In addition, the researchers found that some of the patients had similar symptoms to age-related macular degeneration.
Researchers found that 25% of the patients showed signs of eye damage after taking Elmiron. These included decreased visual function and significant retinal atrophy. The patients had been using the drug for a median of 15 to 18 years.
The Emory study reported that the risk of Elmiron-related eye damage was increased with longer use of the drug. The study also found that patients who were long-term use of Elmiron users had a higher risk of developing a condition known as pigmentary maculopathy. The disease typically affects both eyes.
Taking Elmiron long term can have side effects. There is some evidence that it can cause liver problems. This is why you should speak with your physician before you start taking the drug. It also helps to inform your doctor of any other drugs that you are taking.
Some people who have taken Elmiron have had bruising or bleeding problems. It is also possible that you can develop cataracts or damage to the retina.
The side effects are generally mild. However, some people have experienced blurred vision. You should call your doctor if you notice any changes in your vision.
You should only take Elmiron if you are prescribed it. It is not safe to take the drug while you are pregnant. If you plan on breastfeeding, talk with your doctor about the risks.
Some of the other side effects of Elmiron include tremors, profuse sweating, and trouble walking. It can also make bruising easier. It is also important to take the drug at regular times. If you miss a dose, you should take it at the same time the next day.
Several lawsuits against long term use of Elmiron have been filed in the past two years. These lawsuits focus on patients who suffered from vision problems while taking the drug. This form of legal action is commonly called a mass tort. The lawsuits seek damages for pain and suffering, medical bills, and lost income.
The plaintiffs in these lawsuits claim that Janssen Pharmaceuticals knew or should have known that Elmiron could cause eye damage, but did not warn consumers. The lawsuits also allege that the drug maker withheld information from clinical trials.
The lawsuits against long term use of Elmiron are organized into a multi-district litigation (MDL). This type of lawsuit is similar to a class action. All of the claims are consolidated before a judge, and the plaintiffs are awarded a structured settlement.
According to lawyers who have filed Elmiron lawsuits, the drug has been linked to a number of eye diseases. Specifically, the drug is associated with pigmentary maculopathy, which is characterized by the damage of the macula in the back of the eye. This eye disorder is typically bilateral and causes vision impairment.